ozenoxacin

Details

Files
Generic Name:
ozenoxacin
Project Status:
Complete
Therapeutic Area:
Impetigo
Manufacturer:
Ferrer Internacional, S.A.
Brand Name:
Ozanex
Project Line:
Reimbursement Review
Project Number:
SR0553-000
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the topical treatment of impetigo in patients aged 2 months and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Impetigo
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted December 14, 2017
Patient group input closed February 09, 2018
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groups February 13, 2018
Patient group comments on input summary closed February 21, 2018
Clarification:

- Patient input summary feedback received

Submission received January 25, 2018
Submission accepted for review February 08, 2018
Review initiated February 13, 2018
Draft CDR review report(s) sent to applicant April 30, 2018
Comments from applicant on draft CDR review report(s) received May 09, 2018
Redaction requests from applicant on draft CDR review report(s) received May 16, 2018
CDR review team's comments on draft CDR review report(s) sent to applicant June 08, 2018
Canadian Drug Expert Committee (CDEC) meeting June 20, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans July 05, 2018
Embargo period ended and validation of redacted CDR review report(s) received August 17, 2018
Clarification:

- Request for extension to embargo period received from the manufacturer

- Embargo extension request granted

- Reconsideration requested

Applicant's request for reconsideration placed on CDEC agenda October 17, 2018
CDEC Final Recommendation issued to applicant and drug plans October 24, 2018
CDEC Final Recommendation posted October 26, 2018
Final CDR review report(s) and patient input posted October 29, 2018